tirzepatide triglycerides and other GLP1RA as a novel treatment for patients with congenital generalized lipodystrophy Systemic effects of tirzepatide dually

Contact us today to schedule a consultation with our healthcare professionals

Many of our clients have seen measurable improvements in key health indicators and have even been able to reduce or eliminate medications for conditions like type 2 diabetes and high blood pressure

The UK's NHS has begun evaluating GLP-1 obesity coverage, with NICE's appraisal of semaglutide for obesity resulting in conditional approval for use through specialist weight management services a restrictive but meaningful coverage expansion that will grow over time as service capacity expands

People taking GLP-1 drugs eat less and lose up to 15% of their body weight in a year

The biological targets also differ